Quality assurance of drugs used in clinical trials: proposal for adapting guidelines. by Newton, Paul N et al.
Newton, PN; Schellenberg, D; Ashley, EA; Ravinetto, R; Green, MD;
Kuile, FO; Tabernero, P; White, NJ; Guerin, PJ (2015) Quality as-
surance of drugs used in clinical trials: proposal for adapting guide-
lines. BMJ (Clinical research ed), 350. h602. ISSN 0959-8138 DOI:
10.1136/bmj.h602
Downloaded from: http://researchonline.lshtm.ac.uk/2121413/
DOI: 10.1136/bmj.h602
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
Quality assurance of drugs used in clinical trials:
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Although it is increasingly clear that substandard and falsified
drugs andmedical products (including devices) are an enormous
public health problem,1 2 particularly in the developing world,
clinical trials have largely been considered immune from the
problem.
Clinical trial guidelines from the World Health Organization
and the International Conference onHarmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH) require compliance with applicable good
manufacturing practices for all investigational drugs and
comparators.3 4 But they have not been updated since the 1990s
so they do not include adequate consideration of the current
challenges of the international drug market, where globalised
production and insufficient regulatory overview have resulted
in variable drug quality.5 6
There are many different types of poor quality drugs that could
mistakenly be included in clinical trials, including those with
no, too little, or too much active pharmaceutical ingredient,
those with the wrong active pharmaceutical ingredient, those
with inadequate bioavailability, and those that degrade with
toxic products or contaminants.1 2 6 7 We argue that clinical trial
guidelines (CONSORT, SPIRIT, STARD, and TIDieR) should
include statements on the checking and reporting of the quality
of drugs and medical products used in clinical research. The
WHO and ICH guidelines should also be updated to include
such recommendations.
Scope of problem
We are aware of several examples of clinical trials that have
been conducted or planned using drugs that did not contain what
they were stated to contain. Idindili and colleagues conducted
a double blind, randomised, two arm study comparing the safety
and efficacy of low dose versus high dose vitamin A
supplementation in young Tanzanian infants.8 The vitamin A
capsules used were manufactured by companies in Canada and
Italy. Samples were checked “regularly” during the trial for
vitamin A content. Within 13 months of the trial starting the 50
000 IU capsules had degraded to 32% of the expected amount
of vitamin A, despite being stored under appropriate conditions.
The analyses were adjusted for this major confounder, and the
authors emphasised the need for quality assurance checks of
such capsules in clinical trials and routine supplementation
programmes.
In 2011 a study of the antimalarial drug
sulfadoxine-pyrimethamine in pregnant women in six countries
in Africa was planned using four locally available brands. These
were tested at the US Centers for Disease Control and
Prevention, and the sulfadoxine content of one of the brands
was found to be below 90% of themanufacturer’s stated amount.
An emergency request to procure a good quality brand was
made and the study proceeded with confidence (F ter Kuile,
personal communication, 2015).
Developing countries have limited regulatory capacity for
verifying bioequivalence.9 Drugs containing the same stated
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active pharmaceutical ingredient are not necessarily
bioequivalent if they are produced by different companies or in
different batches. For example, different batches of mefloquine
and digoxin tablets have shown non-bioequivalence.10-13 Thus,
clinical trials using different brands or batches of the same drug
may give different results, which makes interpretation difficult
and can dilute the power of meta-analyses that underlie many
policy recommendations. Sowunmi and colleagues compared
the bioavailability of three brands of oral quinine commonly
available in Nigeria in a formal, randomised, crossover study
in healthy adults.14Alarmingly they found that one of the brands
contained no detectable quinine. This product could well have
been used in a clinical trial of the efficacy of quinine as an
antimalarial drug in Nigeria.
The problem is not confined to developing countries. In 2007
a consignment of clopidogrel labelled as Plavix worth £1m
(€1.3m; $1.5m) for use as a comparator in a clinical trial in the
US was found to be falsified. After initial tests of tablet weight
suggested an abnormality, formal chemical analysis
demonstrated that the tablets contained only 50-80% clopidogrel.
An alternative source of quality assured clopidogrel was used
in the trial. The people responsible for this fraud were linked to
the importation of two million doses of falsified clopidogrel,
olanzapine, and bicalutamide into the United Kingdom. One of
the ringleaders was sentenced to eight years’ imprisonment.15
If the drugs in these examples had not been tested the clinical
trials may have harmed patients, concluded with erroneous
results, and been amajor waste of time and resources.Moreover,
they may have inappropriately informed public health policy.
Although there are examples of poor quality vaccines and
diagnostic tests,1 2 we were unable to find examples of their use
in trials. We suspect that such trials do exist and that their
inconsistent results might contribute to the large number of
clinical trials not published.16 We argue that it is unethical to
recruit patients to clinical trials without appropriate checks to
ensure the adequate quality of drugs and other medical products
used.
Placebo ingredients
A related point is the inclusion of the details of placebo
composition in clinical trial reports.17 For example, placebo
contraceptive pills made of wheat flour, for use within factories,
wrongly found their way into the drug distribution system in
Brazil and resulted in about 200 unplanned pregnancies.18 If
inadvertently used in clinical trials these might cause adverse
events in people with coeliac disease. Similarly placebos that
contain lactose may cause abdominal pain and diarrhoea in
patients who are intolerant to lactose, potentially obscuring the
incidence of these symptoms in the intervention arm. The use
of olive oil and corn oil in placebos in trials of cholesterol
lowering drugs could also skew the results. Golomb and
colleagues found that only 8% of clinical trial reports published
in four medical journals with high impact factors stated the
placebo content and argued that it should be included in the
CONSORT guidelines.17
Guideline adaptation
To ensure that the drugs and medical products used in clinical
trials are of good quality, we suggest that the CONSORT,
SPIRIT, STARD, and TIDieR guidelines are adapted and the
WHO and ICH good clinical practice guidelines are
updated.3 4 19-22
TheWHO and ICH documents do mention the quality of drugs.
The ICH good clinical practice guidelines include the
requirements to ensure stability of investigational product, to
keep sufficient quantities to reconfirm specifications if needed,
and to describe excipients.4
The CONSORT guidelines have been widely adopted to guide
the design, conduct, and reporting of clinical trials.22The SPIRIT
recommendations provide guidance for clinical trial protocols.23
The STARD initiative strives to improve reporting of studies
of diagnostic accuracy, and TIDieR guidelines are aimed at the
description of interventions.24 25 They have been influential in
improving practice and ensuring that trial results appropriately
guide public policy. However, the quality of drugs and other
medical products has not been considered.
We suggest that these guidelines include a requirement to state
the quality of drugs and medical products (including diagnostic
tests evaluated in trials or used for assessing inclusion criteria
or endpoints). Batch numbers and expiry dates of drugs should
also be stated in trial reports and the manufacturers’ certificate
of analysis should be published as supplementary material.
Details of relevant approvals and authorisation numbers from
stringent regulatory authorities (SRAs) should be included for
drugs and placebos in published trial reports. SRAs are the few
national medicine regulatory authorities that are members,
observers, or associates of the ICH.26 If drugs used in the trial
were not manufactured in a country with an SRA or without
such approval the researchers should provide independent
chemical analysis results (including dissolution if appropriate),
and the analytical methods and results should be given in the
supplementary material. Repeat assays should be performed at
intervals during the trial to check for degradation.
For trials with a placebo arm the manufacturer details, including
approval of the manufacturing site and ingredients from the
medicines regulatory authority, should be stated. Investigators
should be advised to use only one batch of each drug in clinical
trials if possible. If different batch numbers are used
sequentially, trial outcomes stratified by batch should be given
in supplementary material. Changes between batches when used
sequentially may represent a “hidden effect of time,” as would
the deleterious effects of poor storage on medical products.27 It
is not expected that the trial should be powered to allow
stratified analysis per batches.
Infrastructural changes
Although these proposals would add a further, albeit mild,
additional reporting requirement, we believe that they are
essential, as this critical weak link in the chain of evidence has
not been addressed. Independent evaluation of trial drugs and
placebos before trials commence and during trials is the only
way to prevent inappropriately informed public health policy.
Systems would be required to allow trialists to find an analytical
laboratory that can provide timely results. Measurement of blood
or plasma drug concentrations should be encouraged. The costs
of analyses will need to be added to funding applications, and
grant awarding bodies should insist on the use and
documentation of quality assured drugs and medical products.
These proposed changes will take time and require the
development of awareness and infrastructure.
Regulatory supervision as well as analytical capacity in the
developing world desperately need strengthening. However, in
the meantime if such testing and documentation is not possible,
the lack of such evidence should be discussed in the report as
a limitation of the study. If drug quality problems are discovered
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they should be reported to the appropriate regulatory authority
and the WHO Rapid Alert System.28
Enormous investment in trials will be wasted and their
interpretation into public policy incorrect if the quality of drugs
and medical products is not assured. Effective drugs may gain
a poor reputation, and the systematic reviews that dominate
policy making may generate incorrect assessments of
heterogeneity or even conclusions. Patients in clinical trials,
like those in routine healthcare, should be offered good quality
assured products.
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Key messages
Although substandard and falsified drugs are an enormous public health problem, particularly in the developing world, their inclusion in
clinical trials has been neglected
Examples from clinical research include the degradation of vitamin A capsules, poor quality sulfadoxine-pyrimethamine for a study of
malaria in pregnancy in Africa, and falsified clopidogrel in the US
Clinical trial guidelines (CONSORT, SPIRIT, STARD, TIDieR) and good clinical practice guidelines from WHO and ICH should include
a requirement to determine and state the quality of drugs
This will require increased awareness and development of infrastructure for accessible analytical capacity. The costs of analyses will
need to be added to trial funding applications, and grant awarding bodies should insist on the use and documentation of quality assured
drugs
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